Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

186.19USD
1:30am IST
Change (% chg)

$2.24 (+1.22%)
Prev Close
$183.95
Open
$182.83
Day's High
$186.32
Day's Low
$182.83
Volume
1,172,376
Avg. Vol
1,717,240
52-wk High
$201.23
52-wk Low
$162.69

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 30.95 32.75
EPS (TTM): 11.00 -- --
ROI: 11.98 14.84 14.38
ROE: 26.43 16.34 16.07

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

15 Jun 2018

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from

15 Jun 2018

Allergan oral migraine drug succeeds in study

June 11 Allergan Plc said on Monday its oral migraine drug met the main goal across all doses in a study, with a statistically significant reduction in monthly headache days in patients with episodic migraine.

11 Jun 2018

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

05 Jun 2018

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)

05 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod

ZURICH, June 1 Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.

01 Jun 2018

U.S. FDA approves Amgen drug for prevention of migraines

Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

Earnings vs. Estimates